| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/22/2004 | CA2491917A1 Altered insulin-like growth factor binding proteins |
| 01/22/2004 | CA2491805A1 Modified adenoviral fiber with ablated binding to cellular receptors |
| 01/22/2004 | CA2491718A1 Process for producing a virus-inactivated thrombin preparation |
| 01/22/2004 | CA2491320A1 Methods and compositions for modulating t helper (th) cell development and function |
| 01/22/2004 | CA2491279A1 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 01/22/2004 | CA2491235A1 Chromosome 3, 5 and 11 genes involved in premature canities |
| 01/22/2004 | CA2490666A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/22/2004 | CA2490278A1 Components of the presenilin-complex |
| 01/22/2004 | CA2489189A1 Bicyclic oligopeptides and their use as glucagon receptor antagonists |
| 01/22/2004 | CA2489174A1 Rna-interference by single-stranded rna molecules |
| 01/21/2004 | EP1382688A1 Screening method |
| 01/21/2004 | EP1382679A2 Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
| 01/21/2004 | EP1382674A2 Alpha-keto acid reductase, method for producing the same, and method for producing optically active alpha-hydroxy acids using the same |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382351A1 Combination therapy of agiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovasuclar disease |
| 01/21/2004 | EP1382350A1 Preventives for postoperative recurrence of premenopausal breast cancer |
| 01/21/2004 | EP1382347A1 Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 01/21/2004 | EP1382346A1 Conditioned medium and diffusible biological product produced by incubating entrapped cells |
| 01/21/2004 | EP1382345A2 Uses of inhibitors of hemostasis |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382334A1 Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| 01/21/2004 | EP1381839A2 Method of imaging cell death in vivo |
| 01/21/2004 | EP1381688A1 Process for the manufacture of a fermented health-promoting product |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381683A2 Human fibroblast growth factor-related compositions |
| 01/21/2004 | EP1381681A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381677A2 Neurotoxins with enhanced target specificity |
| 01/21/2004 | EP1381629A2 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN |
| 01/21/2004 | EP1381628A2 Inflammation-specific peptides and the uses thereof |
| 01/21/2004 | EP1381627A2 Polypeptides derived from amyloid precursor peptide (app) and their uses |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381622A2 Human secreted proteins |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381431A1 Aromatase inhibition to enhance assisted reproduction |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381397A2 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 01/21/2004 | EP1381394A2 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming |
| 01/21/2004 | EP1381392A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same |
| 01/21/2004 | EP1381391A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto |
| 01/21/2004 | EP1381386A2 Novel mixtures of microbial enzymes |
| 01/21/2004 | EP1381385A1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability |
| 01/21/2004 | EP1381384A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa |
| 01/21/2004 | EP1381383A2 Methods of detecting multiple dna binding protein and dna interactions in a sample, and devices, systems and kits for practicing the same |
| 01/21/2004 | EP1381382A2 Methods and compositions for the treatment of diseases of the eye |
| 01/21/2004 | EP1381375A2 Oligonucleotide compositions and their use to induce differentiation of cells |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381361A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 01/21/2004 | EP1381345A2 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
| 01/21/2004 | EP1381276A2 Method of treating or retarding the development of blindness |
| 01/21/2004 | EP1381274A1 Flexible container system for storage of stabilized hemoglobin solutions |
| 01/21/2004 | EP1191942B1 Use of antileukoprotease for the treatment of endometriosis |
| 01/21/2004 | EP1131083B1 Use of growth hormone releasing compounds and their antagonists for the treatment of tumors |
| 01/21/2004 | EP0981366B1 Selective mmp inhibitors having reduced side-effects |
| 01/21/2004 | EP0863982B1 Synthetic hpv11 virus-like particles |
| 01/21/2004 | EP0842276B1 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv) |
| 01/21/2004 | EP0830376B1 Process for producing erythropoietin containing no animal proteins |
| 01/21/2004 | EP0822260B1 Substance fa-70d, process for producing the same, and uses thereof |
| 01/21/2004 | EP0787009B1 Cancer inhibitory peptides |
| 01/21/2004 | EP0759772B1 Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent |
| 01/21/2004 | EP0734263B1 ALPHAvBETA3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS |
| 01/21/2004 | CN1469926A Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/21/2004 | CN1469924A Degraded agonist antibody |
| 01/21/2004 | CN1469883A Peptide selection method |
| 01/21/2004 | CN1469876A Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 01/21/2004 | CN1469871A Substituted dipeptides as growth hormone secretagogues |
| 01/21/2004 | CN1469756A Novel drugs for liver diseases |
| 01/21/2004 | CN1469755A Vaccines containing ribavirin and methods of use thereof |
| 01/21/2004 | CN1469754A Orally administered peptides to ameliorate a therosclerosis |
| 01/21/2004 | CN1469752A Method for treating the central nervous system by administration of IGF structural analogs |
| 01/21/2004 | CN1469736A Use of a porous carrier |
| 01/21/2004 | CN1469734A Pharmaceutical form of administration for peptides, method for its production and use |
| 01/21/2004 | CN1468960A Production process of human lysozyme as AIDS treating medicine with plant as bioreactor |
| 01/21/2004 | CN1468863A Polyglycol-human growth hormone conjugate and its prepn process and medicinal use |
| 01/21/2004 | CN1468861A Recombinant human immune deficiency virus fusion inhibitor and its prepn and use |
| 01/21/2004 | CN1468632A Growth hormone for ovarian functional cell and is prepn |
| 01/21/2004 | CN1468631A Prepn of protein-eliminating pregnant mare blood extractive |
| 01/21/2004 | CN1135236C 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/21/2004 | CN1135223C Aryl-substd propanolamine derivate medicine containing them and their use |
| 01/20/2004 | US6680424 Modified proteinase inhibitors |
| 01/20/2004 | US6680380 Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods |
| 01/20/2004 | US6680375 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer |
| 01/20/2004 | US6680373 Polypeptide for use in the human diagnostics and therapeutics |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680370 Diagnosing defective mesangial cells; glomerulosclerosis, nephritis, and diabetic nephropathy treatment |
| 01/20/2004 | US6680366 Detecting antibodies; drug screening; genetic engineering |
| 01/20/2004 | US6680305 Physiologically acceptable aqueous solutions and methods for their use |
| 01/20/2004 | US6680303 3′,5-difluoro-2′,3′-didehydropyrimidine nucleosides and methods of treatment therewith |
| 01/20/2004 | US6680298 Administering polypeptide to increase serum levels; dietetics, hypoglycemic agents; cardiovascular, autoimmune, kidney, metabolic and nervous system disorder treatment |
| 01/20/2004 | US6680296 Compositions comprising bouganin and a cell binding ligand are particularly useful to kill cells of a target population |
| 01/20/2004 | US6680295 Polypeptide continuously administered by intracerebroventricular infusion at 0.0356 pmol/kg body weight/hour for at least a week |
| 01/20/2004 | US6680294 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/20/2004 | US6680293 Prevention of membrane formation; obtain cell tissue, incubate with inhibitory collagen, monitor membrane formation |
| 01/20/2004 | US6680292 Pharmaceutical composition comprising ribavirin and growth factors and methods of use |
| 01/20/2004 | US6680291 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 01/20/2004 | US6680197 Breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, and t cells that are specific for cells expressing such polypeptides. |
| 01/20/2004 | US6680196 Pd2 gene and its encoded protein for differential diagnosis and therapy of pancreatic adenocarcinomas |
| 01/20/2004 | US6680195 Extracellular matrix-binding proteins from staphylococcus aureus |